A B S T R A C T 17f3-estradiol
INTRODUCTION
Benign prostatic hypertrophy-enlargement of the prostate to the degree that it produces an obstruction of the urethra and(or) rectum -is known to occur commonly in only two species, man and dog (1, 2) . The disorder does not develop in the castrate, and an endocrine etiology has long been suspected. In studies designed to explore the pathogenesis of prostatic hypertrophy, we observed that 17,8-estradiol alone is ineffective in inducing prostatic growth, but 17,8-estradiol has a synergistic effect in promoting growth of the gland in the castrate dog when administered along with the androgen 3a-androstanedioll (3) . Administration of the Received for publication 30 November 1977 in revised form 9 October 1978. 1 Nomenclature used in this paper: Dihydrotestosterone, 17,3-hydroxy-5a-androstan-3-one; 3a-androstanediol, 5a-androstane-3a,17,8-diol; methyltrienolone (R1881), 17,8- hydroxy-17a-methyl-estra-4,9, 1 1-trien-3-one; promegestone (R5020), 17,21-dimethyl-19-nor-pregna-4,9-diene-3,20-dione; triamcinolone acetonide, 9a-fluoro-11/3, 16a, 17a,2 1-tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetonide. two hormones together uniformly results in development of prostatic hypertrophy within 12 wk comparable to that seen in the naturally occurring disorder (3, 4) . The nature of the augmentation of androgen action by estrogen is unknown. We have shown that estrogen has no measurable effect on the metabolism of androgen within the gland (4). However, 17,8-estradiol is known to enhance the production of the progesterone receptor protein in target tissues such as rabbit uterus (5), guinea pig uterus (6), rat breast (7), and human breast (8, 9) . Therefore, experiments were designed to determine whether 17,8-estradiol also regulates activity of the cytoplasmic androgen receptor protein that is believed to be essential for transporting androgen from the cytosol to the nuclear sites of action of the hormone within the prostatic cell.
METHODS
Male mongrel dogs of varying ages and weighing [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] kg were used in these experiments. At the commencement of each study the prostates were exposed through an abdominal incision, three dimensional measurements of the glands were made with calipers (length, width, and depth), and prostate weight was determined as previously described from a nomogram that allows estimation ofactual weight from the apparent volume (3, 4) . Only animals with normal prostates (5-14 g) were used. After the initial measurement of prostate size, the animals were castrated and divided into control and treatment groups. Pharmacological treatment was instituted on the day of castration. The standard dosage consisted of either 1 ml triolein (control) or 1 ml triolein containing 250
,ug 17f8-estradiol (treatment group) administered intramuscularly three times a week (weekly dose, 750 ,ug). The dogs were killed either on day 0 or after 1, 2, 3, or 6 wk, and the prostates were removed, cleaned, weighed, and cut into small fragments. All subsequent procedures were done at 0-4°C.
the supernates (cytosols) were removed for subsequent use. Cytosol preparations contained 11-18 mg protein/ml. Aliquots of the supernates (250 ,ul) were added to tubes in which radioactive steroids in 25 1l methanol had been taken to dryness (final concentration was 3 nM except when indicated). The tubes were mixed and allowed to stand at 0°C for 3 h with repeated mixing at hourly intervals.
[14C]-Albumin (5 Ag, 8,100 dpm) was added, and 0.2 ml of the mixture was layered over a 5.3-ml continuous 5-20% wt/wt sucrose gradient in TEDG buffer. After centrifugation at 50,000 rpm (234,000 g) in a Beckman SW 50.1 rotor (Beckman Instruments, Inc., Spinco Div., Palo Alto, Calif.) for 18.5 h, 10-drop fractions (5-drop fractions in the initial studies) were obtained using a Beckman fraction recovery system (Beckman Instruments, Inc.). 5 ml of counting fluid were added (2,000 ml toluene, 1,000 ml Triton X-100 [Rohm and Haas Co., Philadelphia, Pa.], 80 ml Permafluor [Packard Instrument Co., Downers Grove, Ill.], 210 ml water), and radioactivity was assessed in a Packard 2650 liquid scintillation counter (Packard Instrument Co.) under circumstances in which the counting efficiencies averaged 25% for 3H and 65% for '4C. Sedimentation values were estimated as described by Martin and Ames (10) . In routine assays in which 10-drop fractions were collected, binding in the 8-9S region was estimated as the amount of radioactivity in the peak tube plus four tubes on each side of the peak. In a preliminary series of experiments [3H]dihydrotestosterone binding in the 8-9S region was shown to be stable to freezing in liquid nitrogen for as long as 2 mo, but all the physiological studies reported here were done with fresh cytosol. To assess the extent of metabolism of radioactive ligand during the procedure aliquots ofthe cytosol-hormone mixture were extracted with chloroform-methanol, and thin-layer chromatography was performed on the extracts as described (11 
RESULTS
In the first study the binding of [3H]dihydrotestosterone was assessed in cytosol from a castrated dog (Fig. 1) (18) was even less effective in this regard (Fig. 4) . In addition, the 8 In one, aliquots of castrate control and 17,B-estradioltreated prostates were mixed and homogenized together; in the other, aliquots of the cytosols from the estradiol/wk was incubated with 3 nM radioactive dihydrotestosterone alone or in the presence of a 10-fold excess of testosterone, progesterone, 3a-androstanediol, or dihydrotestosterone. 0.2-ml aliquots of cytosol (containing 3.1 mg protein) were layered on 5-20% sucrose density gradients and analyzed as described in Fig. 1. (C binding after brief exposure to elevated temperature (15 or 30°C for 1 h) was identical for cytosol preparations from control and 17,3-estradiol-treated animals, suggesting that differential stability or differential inactivation by protease did not influence the observed differences between the two treatment groups.
Finally, a time sequence study and a dose-response study were performed. It is of considerable interest that 8S binding was not demonstrable with 3a-androstanediol, whereas in our previous studies 3a-androstanediol had been shown to be a more potent effector of prostatic growth than dihydrotestosterone (3, 4) . It is known, of course, that the interconversion of 3a-androstanediol and dihydrotestosterone takes place in prostate (27, 28) and that when 3a-androstanediol is administered to the rat, dihydrotestosterone is the principal androgen recovered from the prostate nuclei (29) . Considered together with the report that the content of 3a-androstanediol is decreased (30) under conditions in which dihydrotestosterone content is increased in the hypertrophic prostate of man (30, 31) , these findings suggest that dihydrotestosterone may be the effective intracelltular mediator of prostate growth in the dog.
Is it safe to assume that the 8S binding of dihydrotestosterone demonstrable in cytosol, in these studies, is the androgen receptor? Additional work will have to be done to establish the validity of this assumption, but in all other instances in which the androgen receptor has been characterized, such as the mouse kidney anid submandibular gland (11) , the rat prostate (32) , and cultured human fibroblasts (20) , high affinity dihydrotestosterone binding in the 8-1OS region is characteristic of the cytosol receptor. Furthermore, although human prostate is known to contain a progesterone receptor in cytosol (33, 34) , the fact that progesterone and promegestone bind weakly if at all to the 8S moiety characterized here is compatible with our conclusion that the 8S binding is a result of a cytosol receptor that is involved in androgen action. Moreover, progestins are known to compete weakly for binding sites on androgen receptors (35) .
Even if these various assumptions are correct, it does not necessarily follow that the cytosol androgen receptor of human prostate is regulated by estrogen or that the predominant effect of estrogen when given in large quantities is to enhance prostate growth. Indeed, the administration of estrogens in large quantities to intact dogs inhibits prostatic growth, probably as the result of inhibition of gonadotropin release and the secondary induction of a chemical castration, and when administered in large amounts to castrated dogs estrogens cause cystic dilatation but not growth of the prostate (36) . At best, the current results would explain those situations in which elevated estrogen levels occur in the presence ofadequate androgen so that the synergistic effects of the two hormones can be demonstrated.
